Therapy

man speaking

Machine-learning algorithm predicts psychosis from speech

3150 2100 Peter Stevenson, PhD

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

read more
lab

Establishing sNfL as an MS Biomarker

3300 2200 Carlotta Foletti, PhD

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

read more
news

News from the ocrelizumab front

3300 2200 Carlotta Foletti, PhD

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

read more
Doctor

Latest advances in migraine therapy

3682 2200 Carlotta Foletti, PhD

Migraines are the most common type of primary headache disorders, and triptans – serotonin 5-HT1B/1D receptor agonists originally developed as cranial vasoconstrictors – are the backbone of current acute attack…

read more

Could the gut-brain axis have a role in stroke recovery?

3300 2200 Peter Stevenson, PhD

Acute disruption of bacterial populations in the gut after stroke could have a detrimental effect on recovery, according to new research. The role that our microbiome – the microbial environment…

read more

Stem-cell therapy puts the brakes on MS

2850 1900 Peter Stevenson, PhD

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

read more

Cognitive impairment in MS

2048 1153 Mea Holm, PhD

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more

Paralysis patients able to walk after epidural stimulation

3016 1900 Peter Stevenson, PhD

Patients with complete lower limb paralysis after spinal cord injury (SCI) have been given the ability to walk again, it was reported this week. In work published in Nature Medicine,…

read more
Brainwork is supported by unrestricted grants from: